Abstract A new tetracycline-type antibiotic named viridicatumtoxin B along with the known compound viridicatumtoxin has been isolated from the mycelium of liquid fermentation cultures of Penicillium sp. FR11. The structure of viridicatumtoxin B was determined on the basis of MS and NMR data. Viridicatumtoxin B inhibited the growth of Staphylococcus aureus including methicillinresistant S. aureus and quinolone-resistant S. aureus with MIC (m g/ml) of 0.5, which is similar with that of vancomycin, but 8ϳ64 times higher activity than that of tetracycline.
the last-resort antibiotic, vancomycin [2] . Therefore, it is increasingly important and necessary to find new classes of antimicrobials.
In the course of our screening for new anti-MRSA agents from microbial resources, a new tetracycline-type antibiotic named viridicatumtoxin B (1) along with the known compound viridicatumtoxin (2) were isolated from liquid fermentation cultures of Penicillium sp. FR11 (Fig. 1) . Compound 1 is a new epoxide derivative of viridicatumtoxin. Viridicatumtoxin is a tetracycline-type but rare metabolite, which has been once isolated from Penicillium viridicatum [3] . The antibacterial activity of viridicatumtoxin has not been reported. In this paper, we report the fermentation, isolation, structure determination, and antibacterial activity of 1 and 2.
Fermentation and Isolation
The fungal strain FR11 was isolated from a soil sample which was collected around Odae mountain, Kangwon-do, Korea, and identified as Penicillium sp. Fermentation was carried out in a liquid culture medium containing YPS medium (2.0% glucose, 0.2% yeast extract, 0.5% peptone, 0.05% MgSO 4 ·7H 2 O, and 0.1% KH 2 PO 4 , pH 5.7 before sterilization). A piece of the strain FR11 from a mature plate culture was inoculated into a 500-ml Erlenmeyer flask containing 80 ml of the above sterile seed liquid medium and cultured on a rotary shaker (150 rpm) at 28°C for 3 days. For the production of active compounds, 15 ml of the seed culture were transferred into 1000-ml Erlenmeyer flasks containing 300 ml of the YPS medium, and cultivated on a rotary shaker (150 rpm) for 7 days at 28°C. After incubation, the fermented liquid cultures (20 liters) were extracted with 50% Me 2 CO. The Me 2 CO extracts was concentrated in vacuo to an aqueous solution, which was then extracted with an equal volume of EtOAc three times. The EtOAc extract (5. 
Structure Elucidation
The 1 H-and 13 C-NMR spectroscopic data of 2 suggested that this compound is a member of the tetracycline class. Independent interpretation of the 1 H-and 13 C-NMR data together with the 1 H-1 H COSY, DEPT, HMQC, HMBC NMR data led to the identification of 2 as viridicatumtoxin [4] . We found that the C-NMR data is that one quaternary sp 3 carbon (d 116.4) was newly observed in 1 instead of the isolated hydroxy methine (C-5) in 2. In addition, the quaternary sp 2 carbons of C-4a and C-5a were downfield-shifted from d 71.7 and 137.3 to d 77.8 and 144.8, respectively, while the quaternary sp 2 carbon of C-6 was upfield-shifted from d 124.0 and 116.9. These spectral data together with the molecular formula suggested that an epoxide could be formed between C-4a and C-5. The presence of the epoxide moiety was determined by the HMBC spectrum (Fig. 2) . One methylene proton at 2.84 (Ha-4) was long-ranged coupled to the quaternary sp 2 carbons at d 192.9 (C-3) and 99.9 (C-2), and the quaternary sp 3 carbons at d 77.8 (C-4a) and 80.7 (C-12a). The other methylene proton at 3.12 (Hb-4) showed the HMBC correlations with the quaternary sp 2 carbon at C-3 and the quaternary sp 3 carbons at d 116.4 (C-5), indicating that the epoxide is present between C-4a and C-5. The remaining structure was also confirmed by the HMBC spectroscopic data (Fig. 2) and the 13 C-NMR data measured in 225 MHz (Table 2) . Thus, the structure of 1 was assigned as an epoxide derivative of viridicatumtoxin as shown in Fig. 1 . Compound 1 exhibited potent antibacterial activity against S. aureus (S. aureus RN4220 and S. aureus 503), methicillin-resistant S. aureus (S. aureus CCARM 3167 and S. aureus CCARM 3506), and quinolone-resistant S. aureus (S. aureus CCARM 3505 and S. aureus CCARM 3519) with MIC (mg/ml) of 0.5 as shown in Table 3 . The antibacterial activity of 1 against S. aureus, MRSA, and [3] . The absolute configuration of viridicatumtoxin has been determined by X-ray crystallographic methods [5] . The absolute configuration of compound 1 was not determined in this study because of a small amount. Viridicatumtoxin has been known to exhibit antitumor activity [4] . The antibacterial activity of viridicatumtoxin is reported for the first time in this study.
Compounds 1 and 2 showed potent antibacterial activity against several strains of S. aureus including MRSA and QRSA. They exhibited the similar activity with vancomycin, but 8ϳ64 times higher activity than tetracycline. Thus, these compounds may be useful for development of new anti-MRSA agents. 
